Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $77.62 USD
Change Today +0.04 / 0.05%
Volume 494.5K
PCRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM

Pacira Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: David M. Stack, Chairman, Chief Executive Officer and President.

Pacira Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Pacira Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $58.316 million compared to $36.662 million a year ago. Income from operations was $3.341 million compared to loss of $9.258 million a year ago. Income before income taxes was $1.312 million compared to loss of $11.477 million a year ago. Net income was $1.260 million or $0.03 per basic and diluted share compared to net loss of $11.477 million or $0.34 per basic and diluted share a year ago. Non-GAAP net income was $9.812 million or $0.23 per diluted share compared to net loss of $6.467 million or $0.19 per diluted share a year ago. Adjusted EBITDA was $13.5 million. The company provided earnings guidance for the full year of 2015. The company finished first quarter with cash and investments of approximately $175 million. Looking ahead, they are suspending full year 2015 guidance for EXPAREL revenues, and as a logical consequence, we're also suspending guidance on non-GAAP product gross margins.

Pacira Pharmaceuticals, Inc. to Report Q1, 2015 Results on Apr 30, 2015

Pacira Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on Apr 30, 2015

Pacira Pharmaceuticals, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Pacira Pharmaceuticals, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Pacira Pharmaceuticals' Post-Surgical Analgesia Drug Exparel Fails to Secure Expanded Approval by US FDA

Pacira Pharmaceuticals (US) has announced that it has received a complete response letter (CRL) from the US FDA regarding its supplemental New Drug Application filing for Exparel (bupivacaine liposome injectable suspension) as a potential nerve block to provide post-surgical analgesia. The firm has announced that it will schedule a meeting with the Division of Anesthesia, Analgesia and Addiction Products at the FDA's Center for Drug Evaluation and Research to discuss the undisclosed issues that were raised in the CRL.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $77.62 USD +0.04

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.84 USD +0.34
Alkermes PLC $61.35 USD -0.45
Cumberland Pharmaceuticals Inc $6.88 USD +0.08
Durect Corp $2.44 USD +0.10
Halyard Health Inc $41.76 USD -0.29
View Industry Companies
 

Industry Analysis

PCRX

Industry Average

Valuation PCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.8x
Price/Book 15.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.